ERBB2 and Hereditary breast cancer: However, if this approach is applied to a population of ER+ BC with low metastatic heterogeneity (i.e., lobular breast cancer, or ductal breast cancer with a high percentage of ER positive and HER2 negative cells) it could underestimate the actual disease burden since such a clone could show low glucose avidity.